283 related articles for article (PubMed ID: 31897675)
61. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
[TBL] [Abstract][Full Text] [Related]
62. The role of hematopoietic stem cell transplantation in advanced Hodgkin Lymphoma.
Seftel M; Rubinger M
Transfus Apher Sci; 2007 Aug; 37(1):49-56. PubMed ID: 17716946
[TBL] [Abstract][Full Text] [Related]
63. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S
Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455
[TBL] [Abstract][Full Text] [Related]
64. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience.
Rohlfing S; Dietrich S; Witzens-Harig M; Hegenbart U; Schönland S; Luft T; Ho AD; Dreger P
Ann Hematol; 2018 Jul; 97(7):1241-1250. PubMed ID: 29549411
[TBL] [Abstract][Full Text] [Related]
65. [Treatment and prognosis of relapsed or refractory Hodgkin lymphoma patients ineligible for stem cell transplantation].
Móciková H; Sýkorová A; Stěpánková P; Marková J; Michalka J; Král Z; Burešová L; Belada D
Klin Onkol; 2014; 27(6):424-8. PubMed ID: 25493581
[TBL] [Abstract][Full Text] [Related]
66. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.
Spinner MA; Sica RA; Tamaresis JS; Lu Y; Chang C; Lowsky R; Frank MJ; Johnston LJ; Miklos DB; Muffly LS; Negrin RS; Rezvani AR; Shiraz P; Shizuru JA; Weng WK; Binkley MS; Hoppe RT; Advani RH; Arai S
Blood; 2023 Jun; 141(22):2727-2737. PubMed ID: 36857637
[TBL] [Abstract][Full Text] [Related]
67. Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma.
Casulo C; Arcila M; Bohn OL; Teruya-Feldstein J; Maragulia J; Moskowitz CH
Leuk Res; 2013 Sep; 37(9):1178-83. PubMed ID: 23706570
[TBL] [Abstract][Full Text] [Related]
68. Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma.
Bröckelmann PJ; Müller H; Casasnovas O; Hutchings M; von Tresckow B; Jürgens M; McCall SJ; Morschhauser F; Fuchs M; Borchmann P; Moskowitz CH; Engert A
Ann Oncol; 2017 Jun; 28(6):1352-1358. PubMed ID: 28327958
[TBL] [Abstract][Full Text] [Related]
69. Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany.
Zagadailov EA; Corman S; Chirikov V; Johnson C; Macahilig C; Seal B; Dalal MR; Bröckelmann PJ; Illidge T
Leuk Lymphoma; 2018 Jun; 59(6):1413-1419. PubMed ID: 29045163
[TBL] [Abstract][Full Text] [Related]
70. Immunotherapy for the treatment of Hodgkin lymphoma.
Donato EM; Fernández-Zarzoso M; De La Rubia J
Expert Rev Hematol; 2017 May; 10(5):417-423. PubMed ID: 28359170
[TBL] [Abstract][Full Text] [Related]
71. Role of Consolidative Radiation Therapy After Autologous Hematopoietic Cell Transplantation for the Treatment of Relapsed or Refractory Hodgkin Lymphoma.
Wilke C; Cao Q; Dusenbery KE; Bachanova V; Lazaryan A; Lee CK; Yuan J
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):94-102. PubMed ID: 28816170
[TBL] [Abstract][Full Text] [Related]
72. Outcomes of Refractory and Relapsed Hodgkin Lymphoma With Autologous Stem-Cell Transplantation: A Single Institution Experience.
Wali R; Saeed H; Patrus N; Javed S; Khan SJ
J Glob Oncol; 2019 Nov; 5():1-6. PubMed ID: 31756138
[TBL] [Abstract][Full Text] [Related]
73. Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma.
Bains T; Chen AI; Lemieux A; Hayes-Lattin BM; Leis JF; Dibb W; Maziarz RT
Leuk Lymphoma; 2014 Mar; 55(3):583-7. PubMed ID: 23697844
[TBL] [Abstract][Full Text] [Related]
74. Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience.
Casadei B; Argnani L; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Cavo M; Zinzani PL
Hematol Oncol; 2020 Dec; 38(5):737-741. PubMed ID: 32905626
[TBL] [Abstract][Full Text] [Related]
75. Reassessment of risk factors and long-term results of autologous stem cell transplantation in relapsed and refractory classical Hodgkin lymphoma.
Fatobene G; Linardi CDCG; Moreira F; Targueta GMF; Santos FM; Velasques RD; Rocha V; Buccheri V
Hematol Oncol; 2019 Aug; 37(3):310-313. PubMed ID: 30847943
[No Abstract] [Full Text] [Related]
76. High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant.
Castagna L; Crocchiolo R; Giordano L; Bramanti S; Carlo-Stella C; Sarina B; Chiti A; Mauro E; Gandolfi S; Todisco E; Balzarotti M; Anastasia A; Magagnoli M; Brusamolino E; Santoro A
Bone Marrow Transplant; 2015 Apr; 50(4):499-504. PubMed ID: 25621797
[TBL] [Abstract][Full Text] [Related]
77. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.
Manson G; Mear JB; Herbaux C; Schiano JM; Casasnovas O; Stamatoullas A; Deau B; Schmitt A; Garnier G; Regny C; Bouabdallah K; Moles-Moreau MP; Ghesquieres H; Tempescul A; Dulery R; Nicolas-Virelizier E; Delmer A; Borel C; Chauchet A; Damotte D; Dercle L; Brice P; Houot R;
Eur J Cancer; 2019 Jul; 115():47-56. PubMed ID: 31082693
[TBL] [Abstract][Full Text] [Related]
78. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.
Landsburg DJ; Falkiewicz MK; Maly J; Blum KA; Howlett C; Feldman T; Mato AR; Hill BT; Li S; Medeiros LJ; Torka P; Hernandez-Ilizaliturri F; Reddy NM; Singavi A; Fenske TS; Chavez JC; Kaplan JB; Behdad A; Petrich AM; Bast MA; Vose JM; Olszewski AJ; Costa C; Lansigan F; Gerson JN; Barta SK; Calzada O; Cohen JB; Lue JK; Amengual JE; Rivera X; Persky DO; Peace DJ; Nathan S; Cassaday RD
J Clin Oncol; 2017 Jul; 35(20):2260-2267. PubMed ID: 28475457
[TBL] [Abstract][Full Text] [Related]
79. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
Moskowitz CH; Walewski J; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Viviani S; Bachanova V; Sureda A; McClendon T; Lee C; Lisano J; Sweetenham J
Blood; 2018 Dec; 132(25):2639-2642. PubMed ID: 30266774
[TBL] [Abstract][Full Text] [Related]
80. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.
Bonthapally V; Yang H; Ayyagari R; Tan RD; Cai S; Wu E; Gautam A; Chi A; Huebner D
Curr Med Res Opin; 2015; 31(7):1377-89. PubMed ID: 25950500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]